Conference Coverage
Conference Coverage
VIDEO: U.S. hepatitis C treatment capacity falls short of need
Despite new hepatitis C treatment options, the health care system’s capacity to treat patients still falls far short of what’s needed.
Conference Coverage
AASLD: HCV cure associated with reduction in all-cause mortality
Sustained virologic response in patients with hepatitis C virus infection is associated with large reductions in all-cause mortality and appears...
Conference Coverage
AASLD: Pilot study shows value of response-guided therapy for HCV GT1b
Response-guided therapy using all-oral triple direct-acting antiviral therapy appears useful for shortening the duration of treatment in...
Conference Coverage
Elevated liver cancer risk after HCV cure may justify surveillance
Sustained virologic response in patients with well controlled hepatic C virus infection does not protect select subgroups of this cohort from...
Conference Coverage
Investigational hepatitis B therapy shows activity in proof-of-concept study
NVR 3-778, an experimental hepatitis B virus core inhibitor, showed substantial activity and was well tolerated in an initial phase Ib study.
Conference Coverage
Transplant waiting-list registrations dropped after direct acting–antiviral approval
The number of new waiting-list registrations for liver transplantation among patients with hepatitis C virus declined significantly after the...
Conference Coverage
Interferon-free treatment combo looks promising for HCV GT2, GT3 infection
The investigational combination of ombitasvir, paritaprevir, and ritonavir when given with sofosbuvir (OBV/PTV/r + SOF) appears to be a highly...
Conference Coverage
VIDEO: 12-week HCV retreatment effective if short course fails
Patients who fail short-course treatment for hepatitis C and show high levels of resistance to an antiviral drug may still respond to standard 12-...
Conference Coverage
Sofosbuvir/R yields benefits in compassionate use HCV program
In real-world setting, sofosbuvir in combination with ribavirin (SOF/R) provided meaningful benefits for special populations with hepatitis C...
Conference Coverage
VIDEO: Longer HCV therapy worked even after short-term failures
Patients with HCV who fail short-course antiviral treatment may still be able to achieve a cure using longer-duration therapies plus ribavirin.
Conference Coverage
Multitargeted drug combination promising when new HCV antivirals fail
Key clinical point: A five-drug antiviral combination appears to be effective for retreatment of patients with hepatitis C virus infection who...